A total of 428 patients treated with first-line ET + CDK4/6i between January 2015 and April 2022 were included in this study; of these, 269 (62.8%) patients had HER2-low disease, while the 159 (37.2%) patients had HER2-0 BC. Here, CDK4 is linked to breast cancer.